Contact Us
Drug Search Results
Using advanced filters...
Advanced Search [+]

ACE-1831

Alternative Names: ACE-1831, ACE1831, ACE 1831
Latest Update: 2024-11-15
Latest Update Note: News Article

Product Description

A novel allogeneic alpha CD-20-conjugated V delta 2 gamma delta T product for non-Hodgkin’s Lymphoma. ACE 1831 represents a novel off-the-shelf treatment for B cell malignancies with potency, cost efficiency and safety advantage. (Sourced from: https://www.acepodia.com/newsroom-detail/Acepodia_Presents_Preclinical_Data_on_its_gamma_delta_T_cell_Therapy_Candidate_ACE1831_at_2022_AACR_Meeting/)

Mechanisms of Action: Cell Therapy,CD20

Novel Mechanism: Yes

Modality: Cell Therapy

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Acepodia Biotech
Company Location:
Company CEO:
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for ACE-1831

Countries in Clinic: United States

Active Clinical Trial Count: 1

Highest Development Phases

Phase 1: B-Cell Marginal Zone Lymphoma|Diffuse Large B-Cell Lymphoma|Follicular Lymphoma

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
ACE1831-001

P1

Recruiting

Diffuse Large B-Cell Lymphoma|Follicular Lymphoma|B-Cell Marginal Zone Lymphoma

2025-09-01

2%

Recent News Events

Date

Type

Title

11/15/2024

News Article

 Acepodia Announces FDA Clearance of Investigational New Drug Application for ACE1831 in IgG4-Related Disease

09/03/2024

News Article

 Acepodia Enters Strategic Clinical Collaboration with Pfizer to Accelerate Development of Antibody-Cell Conjugation-Based Cell Therapies in Autoimmune Diseases

05/08/2024

News Article

 Acepodia Announces Preliminary Clinical Data From Phase 1 Clinical Trial of ACE1831, First-Ever Anti-CD20 Antibody Conjugated Allogenic Gamma Delta T Cell Therapy for Non-Hodgkins Lymphoma

06/06/2023

News Article

 Acepodia Secures $100 Million Series D Financing to Advance

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions